|
Cancer Research Technology Sources New Antibodies and Cell Lines in Commercialisation Deal with the Leukaemia Research Immunodiagnostics Unit of the University of Oxford
23rd February 2006 – Cancer Research Technology Limited (CRT, the specialist technology development and commercialisation company), has signed an agreement to commercialise a large number of monoclonal antibodies from The University of Oxford.
Under this agreement, CRT will commercialise antibodies and hybridoma cell lines produced by Leukaemia Research-funded scientists in the Nuffield Department of Clinical Laboratory Sciences, John Radcliffe Hospital, University of Oxford. A number of these researchers are members of the The Leukaemia Research Immunodiagnostics Unit, which has specialised over many years in antibody production and has a long-standing reputation in lymphoma research. In addition, the Unit initiated several years ago a hybridoma production service that aims to raise antibodies for other Leukaemia Research-funded laboratories.
This relationship will add in excess of 60 new products from Oxford to CRT’s existing portfolio of more than 350 antibodies available for licensing, and also includes monoclonal antibodies to be produced in the Immunodiagnostics Unit in the future.
Establishing partnerships with academic facilities and institutes for reagent commercialisation, independent of funding from Cancer Research UK, represents a new strategy for CRT and builds on a similar agreement completed with the National Institute for Biological Standards and Control (NIBSC). By initiating such relationships, CRT utilises its expertise and experience in diagnostic and research tool commercialisation to partner reagents with commercial suppliers and provide the scientific community with access to important research tools.
For further information:
Notes for editors:
Cancer Research Technology Limited
Cancer Research Technology Limited (CRT) is a specialist technology transfer company which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is wholly owned by Cancer Research UK, the largest independent funder of cancer research in the world. CRT works closely with leading international cancer scientists and their institutes to protect intellectual property arising from their research and to establish links with commercial partners. CRT facilitates the discovery, development and marketing of new cancer therapeutics, vaccines, diagnostics and enabling technologies. Further information about CRT can be found at www.cancertechnology.com.
The University of Oxford
Oxford University, the oldest university in the English-speaking world, is an international leader in medical research. The Nuffield Department of Clinical Laboratory Sciences brings together all of the clinical laboratory based disciplines within the Oxford Medical School (Microbiology, Genetics, Cellular Pathology, Haematology and Clinical Biochemistry).
Leukaemia Research
Leukaemia Research is the only national charity devoted exclusively to improving treatments, finding cures and learning how to prevent leukaemia, Hodgkin's lymphoma and other lymphomas, myeloma and the related blood disorders, diagnosed in 24,500 people in the UK every year. Over the next five years, Leukaemia Research is committing over £100million to new leading research. From basic laboratory research to clinical trials with patients, the charity is committed to saving lives by funding high quality, carefully selected, research throughout the UK. Further information about blood cancers and the charity is available from www.lrf.org.uk or by calling 0207 405 0101
|
